Insights › Science & technology › November 19, 2026
Science & technology · Pipeline & development

Actinium-225 Pretargeted Radioimmunotherapy against Colorectal Cancer using Self-Assembling and Disassembling Antibodies

bioRxiv (Pharmacology) Published: Preprint

Colorectal cancer (CRC) remains a leading cause of cancer deaths worldwide. GPA33, expressed on 95% of CRC, has been extensively targeted by IgG-attached payloads in conventional radioimmunotherapy (RIT), but toxicity was dose-limiting. A 2-step pretargeted radioimmunotherapy (PRIT) regimen using Self-Assembling-Disassembling antibody (SADA) specific for GPA33 (10 mg/kg) intravenous (IV) in step #

Original source
Read the source — biorxiv.org ↗

We link to the original publisher. The summary above is a short guide; read the original for the full details.

More in Science & technology

See everything in Science & technology →

Look into this further

Read every record in your own language

This page shows the three newest items per field. Members see every record in the field, in 109 languages, with the search engines that work on them.

Read it all — start from $3No app-store installation. Cancel any time.